Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidn… Read more
Maze Therapeutics, Inc. Common Stock (MAZE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.065x
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) has a cash flow conversion efficiency ratio of -0.065x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.64 Million) by net assets ($379.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Maze Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Maze Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maze Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Societatea Nationala de Transport Gaze Naturale Transgaz SA
RO:TGN
|
0.016x |
|
A10 Network
NYSE:ATEN
|
0.107x |
|
Minmetals Capital Co Ltd
SHG:600390
|
0.064x |
|
Shenyang Machine Tool Co Ltd
SHE:000410
|
0.062x |
|
CPFL Energia S.A
SA:CPFE3
|
0.053x |
|
Yantai Dongcheng Pharmaceutical Co Ltd
SHE:002675
|
0.014x |
|
Cetc Potevio Science&Technology Co Ltd
SHE:002544
|
-0.016x |
|
Beijing YanDong MicroElectronic Co. Ltd. A
SHG:688172
|
N/A |
Annual Cash Flow Conversion Efficiency for Maze Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Maze Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $196.90 Million | $75.95 Million | 0.386x | +104.47% |
| 2023-12-31 | $10.05 Million | $-86.83 Million | -8.636x | -783.11% |
| 2022-12-31 | $101.44 Million | $-99.20 Million | -0.978x | -- |